#pharmaceuticals
articles
Diabetes Treatment Is a $966 Billion Global Market Led by Novo Nordisk, Eli Lilly and Sanofi
Nearly 537 million people live with diabetes, and global health spending reached an estimated $966 billion in 2021. Here...
Telehealth 'Pill Mills' Are Turning Easy Access Into a Patient-Safety Problem
Cash-pay telehealth sites are prescribing GLP-1s, ketamine and other drugs after minimal screening. Clinicians and a JAM...
Mozambique's State Drug Company SMM Reports 98.5% Profit Drop, Group Swings to Loss
Sociedade Moçambicana de Medicamentos earned only €137,000 in 2025 as exceptional Infarma gains faded and sales nearly h...
Eli Lilly’s Revenue Remains Overwhelmingly Tied to Endocrinology
With 74% of sales coming from endocrinology, the US drugmaking giant’s fortunes hinge on diabetes and obesity therapies....
Russia's Health Ministry Recommends 9 New Drugs for Vital List, Only 4 Made Locally
The proposal seeks to expand state-funded access to cancer, rare disease and diabetes treatments, with most therapies su...
Diabetes Market Surges Past $966 Billion as Patient Count Tops 537 Million
Global diabetes spending reached nearly $966 billion in 2021, driven by a disease burden affecting 10% of the world's po...
Pharma Industries Bets $10M to Make Paraguay a Medicinal Cannabis Hub
Paraguayan pharma group Pharma Industries unveils TodoCANN, a pharmaceutical-grade medicinal cannabis line, backed by ov...
Biotech investing: chasing the thrill of clinical success amid extraordinary risk
Biotechnology stocks have become a standalone investment theme, blending breakthrough science with extreme volatility. H...
Novo Nordisk's Wegovy Pill Heads to Germany as Shares Slip on Pipeline Setback
Oral Wegovy is coming to Germany, but a CagriSema trial setback and modest pill sales tempered Novo Nordisk's guidance r...
AstraZeneca–BMS Merger Report Sends Shares Tumbling Into Antitrust Spotlight
Investors sold AstraZeneca after a report it held preliminary merger talks with Bristol Myers Squibb, while analysts que...
Novo Nordisk Sheds $30 Billion as Heart Drug Trial Fails, Derailing Diversification Hopes
A late-stage trial of Novo Nordisk's cardiovascular drug ziltivekimab failed to meet its primary goal, wiping out a pote...
Eli Lilly's Mounjaro Hits R$13.5 Billion in First Year in Brazil, Reshaping Obesity Drug Market
Demand for tirzepatide outstripped expectations, boosting the Brazilian unit into Eli Lilly's global top 10, but looming...
Grifols Appoints Former GSK Vaccines Executive to Board, Replacing Portobello Founder
Joanna Le Couilliard, a pharmaceutical veteran with deep vaccine and Asia-Pacific experience, joins Grifols as independe...
Anvisa Approves Five New Semaglutide Pens, Heating Up Brazil's R$5.6 Billion Weight-Loss Drug War
Brazil's health regulator cleared five additional semaglutide pens from Sandoz, Sun Pharma, Ranbaxy, and Brainfarma, sha...
GSK to Close Stevenage R&D Hub in £1.9bn Cost Drive, Opens Cambridge Flagship
The drugmaker will move 1,800 staff from its historic Stevenage centre to a new Cambridge site, launching a three-year c...
Johnson & Johnson Agrees to $5.5 Billion Talc Settlement to End 15-Year Litigation
The pharmaceutical giant aims to resolve tens of thousands of ovarian cancer claims with a $5.5 billion deal, seeking cl...
How the US Section 301 Tariff's 10% Levy Will Reshape Indian Export Competitiveness
A new 10% US tariff on Indian imports under Section 301 is stoking exporter anxiety, yet many sectors face similar hurdl...
arGEN-X to Acquire Forte Biosciences in $2.2 Billion Immunology Pipeline Deal
Dutch biotech arGEN-X is buying US-based Forte Biosciences for $2.2 billion, adding a promising anti-CD122 antibody for ...
Scientists Uncover Neuron 'Gatekeeper' That Could Lead to New Alzheimer's Therapies
Discovery of a cellular skeleton's gatekeeping role links endocytosis to Alzheimer's plaque formation, opening a fresh a...